196 related articles for article (PubMed ID: 30103170)
1. Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment.
Chung SW; Kim GC; Kweon S; Lee H; Choi JU; Mahmud F; Chang HW; Kim JW; Son WC; Kim SY; Byun Y
Biomaterials; 2018 Nov; 182():35-43. PubMed ID: 30103170
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.
Kwak G; Jo SD; Kim D; Kim H; Kim MG; Kim K; Kwon IC; Kim SH
J Control Release; 2017 Dec; 267():203-213. PubMed ID: 28823674
[TBL] [Abstract][Full Text] [Related]
3. Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity.
Mazzucchelli S; Bellini M; Fiandra L; Truffi M; Rizzuto MA; Sorrentino L; Longhi E; Nebuloni M; Prosperi D; Corsi F
Oncotarget; 2017 Jan; 8(5):8383-8396. PubMed ID: 28039473
[TBL] [Abstract][Full Text] [Related]
4. The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy.
Zhou ZR; Yang ZZ; Wang SJ; Zhang L; Luo JR; Feng Y; Yu XL; Chen XX; Guo XM
Acta Pharmacol Sin; 2017 Apr; 38(4):513-523. PubMed ID: 28042876
[TBL] [Abstract][Full Text] [Related]
5. Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors.
Hubackova S; Davidova E; Boukalova S; Kovarova J; Bajzikova M; Coelho A; Terp MG; Ditzel HJ; Rohlena J; Neuzil J
Cell Death Dis; 2020 Feb; 11(2):110. PubMed ID: 32034120
[TBL] [Abstract][Full Text] [Related]
6. Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells.
Herůdková J; Paruch K; Khirsariya P; Souček K; Krkoška M; Vondálová Blanářová O; Sova P; Kozubík A; Hyršlová Vaculová A
Neoplasia; 2017 Oct; 19(10):830-841. PubMed ID: 28888100
[TBL] [Abstract][Full Text] [Related]
7. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
[TBL] [Abstract][Full Text] [Related]
8. MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
Bridges KA; Chen X; Liu H; Rock C; Buchholz TA; Shumway SD; Skinner HD; Meyn RE
Oncotarget; 2016 Nov; 7(44):71660-71672. PubMed ID: 27690219
[TBL] [Abstract][Full Text] [Related]
9. Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management.
Mahmud F; Chung SW; Alam F; Choi JU; Kim SW; Kim IS; Kim SY; Lee DS; Byun Y
J Control Release; 2017 Mar; 249():42-52. PubMed ID: 28093298
[TBL] [Abstract][Full Text] [Related]
10. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.
Dai Y; Chen S; Kmieciak M; Zhou L; Lin H; Pei XY; Grant S
Mol Cancer Ther; 2013 Jun; 12(6):878-89. PubMed ID: 23536721
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer.
Chang AE; Wu QV; Jenkins IC; Specht JM; Gadi VK; Gralow JR; Salazar LG; Kurland BF; Linden HM
Clin Breast Cancer; 2018 Feb; 18(1):e143-e149. PubMed ID: 29174203
[TBL] [Abstract][Full Text] [Related]
12. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas.
Mainetti LE; Rico MJ; Fernández-Zenobi MV; Perroud HA; Roggero EA; Rozados VR; Scharovsky OG
Ann Oncol; 2013 Sep; 24(9):2310-6. PubMed ID: 23666914
[TBL] [Abstract][Full Text] [Related]
15. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy-assisted tumor selective metronomic oral chemotherapy.
Chung SW; Kweon S; Lee BS; Kim GC; Mahmud F; Lee H; Cho YS; Choi JU; Jeon OC; Kim JW; Kim SW; Kim IS; Kim SY; Byun Y
Int J Cancer; 2017 Nov; 141(9):1912-1920. PubMed ID: 28635011
[TBL] [Abstract][Full Text] [Related]
17. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer.
Li JA; Song C; Rong Y; Kuang T; Wang D; Xu X; Yuan J; Luo K; Qin B; Nowsheen S; Lou Z; Lou W
Cell Cycle; 2018; 17(2):191-199. PubMed ID: 29157102
[TBL] [Abstract][Full Text] [Related]
18. Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs.
Rasmussen RM; Kurzman ID; Biller BJ; Guth A; Vail DM
Vet Comp Oncol; 2017 Jun; 15(2):421-430. PubMed ID: 26522053
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
20. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.
Zenvirt S; Kravchenko-Balasha N; Levitzki A
Oncogene; 2010 Nov; 29(46):6149-59. PubMed ID: 20729914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]